AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11500288
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of open-ended test questions by paper-and-pencil
Trial: 9929147
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy with external dose > 60 Gy
Trial: 7880702
Drug: suxamethonium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 0.5 mg kg‐1
Trial: 7917735
Drug: suxamethonium 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 3.0 mg kg‐1
Trial: 31023863
Drug: 80 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/m2 solvent-based paclitaxel (PACL80/w)
Trial: 31023863
Drug: 100 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/m2 nab-paclitaxel (NAB100/w)
Trial: 31023863
Drug: 150 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/m2 nab-paclitaxel (NAB150/w)
Trial: 31023863
Drug: 150 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/m2 nab-paclitaxel (NAB150/2w)
Trial: 24303975
Drug: Levocetirizine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine (5 mg once daily)
Trial: 21142269
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of paroxetine and itraconazole
Trial: 16707412
Drug: Liquid etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liquid etanercept (50 mg/mL)
Trial: 16707412
Drug: Reconstituted lyophilized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstituted lyophilized etanercept (25 mg/mL)
Trial: 12702524
Drug: Arm A
RxNorm normalized name: Warm antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A (cisplatin 25 mg/m(2) day 1, weekly for 9 weeks, irinotecan 90 mg/m(2) day 1, on weeks 1, 3, 5, 7 and 9, etoposide 60 mg/m(2) days 1‐3, on weeks 2, 4, 6, 8)
Trial: 12702524
Drug: Arm B
RxNorm normalized name: arm brace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B (cisplatin 60 mg/m(2) day 1, irinotecan 60 mg/m(2) days 1, 8, 15, etoposide 50 mg/m(2) days 1‐3, every 4 weeks for four cycles)
Trial: 4057034
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg intramuscularly as a pre-anesthetic
Trial: 29985964
Drug: Postnatal dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Postnatal dexamethasone treatment
Trial: 24803825
Drug: Radiotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy alone (non-drug group)
Trial: 22044195
Drug: Pomegranate Seed
RxNorm normalized name: pomegranate seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate Seed Oil (PSO) 400 mg capsules twice daily for 4 weeks
Trial: 22044195
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules twice daily for 4 weeks
Trial: 20488410
Drug: Nonoverlapping drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoverlapping drug-eluting stents (DES)
Trial: 20488410
Drug: Overlap segments
RxNorm normalized name: Seglentis
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Overlap segments of drug-eluting stents (DES)
Trial: 18630591
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) treatment with 'Xiusanzhen' technique.
Trial: 18630591
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (Duxil, 40 mg/time, 2 times/d for 10 weeks).
Trial: 15951469
Drug: Body surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body surface area-based dosing
Trial: 10715370
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of tamoxifen twice daily for 1 day followed by 800 micrograms of saline‐moistened misoprostol vaginally
Trial: 10715370
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 1 day followed by 800 micrograms of saline‐moistened misoprostol vaginally
Trial: 10715370
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of tamoxifen
Trial: 10715370
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of tamoxifen and misoprostol
Trial: 1952856
Drug: Ciprofloxacin, 500
RxNorm normalized name: Ciprofloxacin, 500 mg/5 mL oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin, 500 mg every 12 h orally for 7 to 10 days
Trial: 1952856
Drug: Parenteral aminoglycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral aminoglycoside for 7 to 10 days
Trial: 7064026
Drug: Atropine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.6 mg after metoclopramide
Trial: 7064026
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg after atropine
Trial: 26905985
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of magnesium sulphate intravenously
Trial: 22269160
Drug: Memantine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (20 mg/day after up-titration over 4 weeks)
Trial: 22269160
Drug: Patients not
RxNorm normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients not treated with acetyl cholinesterase inhibitors (AChEIs)
Trial: 20680188
Drug: Escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 mg/d for 4 weeks
Trial: 18522664
Drug: QI-Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QI-Therapy
Trial: 17632164
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg dutasteride daily
Trial: 2229286
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (0.625 mg/day; n = 7)
Trial: 860743
Drug: Sensory integrative
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensory integrative therapy
Trial: 29183393
Drug: Prophylactic penehyclidine
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic penehyclidine inhalation
Trial: 29183393
Drug: Placebo (water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (water for injection)
Trial: 26380437
Drug: Qingyuan Shenghua
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingyuan Shenghua Decoction (QSD), one dose per day for 1 week
Trial: 24377215
Drug: Chen's needling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chen's needling therapy
Trial: 24377215
Drug: Conventional needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional needling therapy
Trial: 24377215
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between Chen's needling therapy and Conventional needling therapy
Trial: 8039530
Drug: MK-0434 (0.1-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0434 (0.1-100 mg)
Trial: 1002100
Drug: Contrapect (new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrapect (new antitussive principle)
Trial: 28528395
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of fractional CO2 laser therapy and hair growth factors
Trial: 16541115
Drug: Tadalafil treatment
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil treatment
Trial: 19344226
Drug: Lower SHBG
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower SHBG (Sex Hormone-Binding Globulin)
Trial: 9492508
Drug: Low flow
RxNorm normalized name: high mallow flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low flow anesthesia (group L): oxygen 0.5 l.min‐1, nitrous oxide 0.5 l.min‐1, isoflurane
Trial: 9492508
Drug: Standard flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard flow anesthesia (group H): oxygen 2 l.min‐1, nitrous oxide 4 l.min‐1, isoflurane
Trial: 4204790
Drug: 3200 IU
RxNorm normalized name: sodium chloride 3200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3200 IU of vitamin E daily
Trial: 4204790
Drug: Regular daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular daily dose of vitamin E (400 to 2400 IU)
Trial: 24577164
Drug: Bevacizumab added
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab added to chemotherapy
Trial: 24637997
Drug: Single-agent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent chemotherapy alone
Trial: 23741997
Drug: SRP+topical gaseous
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP+topical gaseous ozone
Trial: 21273939
Drug: HPV‐16/18 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV‐16/18 vaccine administered according to the alternative schedule (0‐1‐12 months)
Trial: 21273939
Drug: HPV‐16/18 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV‐16/18 vaccine administered according to the standard schedule (0‐1‐6 months)
Trial: 11913307
Drug: Experimental gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental gum formulations
Trial: 9286747
Drug: Calcium supplements
RxNorm normalized name: CALCIUM SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplements (mean calcium dose: 1050 mg)
Trial: 7950469
Drug: Educational sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational sessions for physicians to standardize knowledge of the recommendations of the Canadian Hypertension Society on hypertension treatment and specific operational incentives to improve hypertension control.
Trial: 2438648
Drug: 4 ABVD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ABVD chemotherapy
Trial: 28718232
Drug: Intravenous steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous steroids (120 mg of injection Depomedrol) administered 1 hour before surgery
Trial: 28718232
Drug: Conventional MRM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional MRM without steroids (Group A)
Trial: 23843375
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT) protocol consisting of myofascial release to the thoracic inlet, the splenic pump, and the pedal lymphatic pump for 6 minutes.
Trial: 23843375
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT) protocol
Trial: 21926038
Drug: Cryosurgery during
RxNorm normalized name: Pro-C-Dure 6 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryosurgery during daily imiquimod application (Arm I)
Trial: 11533366
Drug: Montelukast 4
RxNorm normalized name: montelukast 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 4 mg chewable tablet
Trial: 9506726
Drug: Levothyroxine (L‐T4)
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (L‐T4) suppressive therapy
Trial: 8172437
Drug: Fluconazole, 150
RxNorm normalized name: Fluconazole, 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole, 150 mg, once daily
Trial: 8172437
Drug: Oral amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral amphotericin B, 500 mg every 6 hours
Trial: 31072385
Drug: Compliant regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compliant regular users (C-RU) of advanced PAP therapy
Trial: 31072385
Drug: Subthreshold users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subthreshold users (SC-RU) of advanced PAP therapy
Trial: 31072385
Drug: Noncompliant users
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Noncompliant users (NC-MU) of advanced PAP therapy
Trial: 31072385
Drug: Hours of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hours of weekly PAP use
Trial: 30066463
Drug: 6-month support
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month support programme consisting of psychoeducation, social support, and behavioural cognitive therapy
Trial: 25141110
Drug: 1.0 W/cm2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 W/cm2 continuous ultrasound treatment
Trial: 25141110
Drug: 1.0 W/cm2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 W/cm2 1:4 pulsed ultrasound treatment
Trial: 25141110
Drug: 0 W/cm2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 W/cm2 ultrasound treatment (placebo)
Trial: 21707451
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation, 2 g/day for 15 days
Trial: 18973889
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral contraceptive containing ethinyl estradiol and drospirenone for three cycles
Trial: 16395988
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine in combination with oral antidiabetic drugs (OADs)
Trial: 16395988
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus OADs
Trial: 8594942
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) infusion (2 pmol.kg‐1.min‐1 for 2 h)
Trial: 2242369
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of salbutamol orally 30 min before vaginal administration of 2 mg prostaglandin E2 gel
Trial: 2242369
Drug: Placebo orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally 30 min before vaginal administration of 2 mg prostaglandin E2 gel
Trial: 2242369
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of salbutamol
Trial: 15277410
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin aspart every hour (SC-1h)
Trial: 15277410
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin aspart every 2 hours (SC-2h)
Trial: 15277410
Drug: Intravenous regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous regular insulin (IV)
Trial: 9205509
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg terbinafine daily for 6 weeks
Trial: 8763463
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg terbinafine daily for 12 weeks
Trial: 9205509
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg terbinafine daily for 6 weeks (in patients with fingernail infection)
Trial: 22854553
Drug: A-solution (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-solution (oral gargling with blended essential oils diluted with distilled water)
Trial: 7250591
Drug: Digoxin (0.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.375 mg/day)
Trial: 7250591
Drug: Beta-methyldigoxin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-methyldigoxin (0.25 mg/day)
Trial: 27980008
Drug: Arhalofenate 800
RxNorm normalized name: Arhalofenate
DrugBank: Arhalofenate (DB11811)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arhalofenate 800 mg + Febuxostat 80 mg
Trial: 27980008
Drug: Arhalofenate 600
RxNorm normalized name: Arhalofenate
DrugBank: Arhalofenate (DB11811)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arhalofenate 600 mg + Febuxostat 80 mg
Trial: 27980008
Drug: Arhalofenate 800
RxNorm normalized name: Arhalofenate
DrugBank: Arhalofenate (DB11811)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arhalofenate 800 mg + Febuxostat 40 mg
Trial: 27980008
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Arhalofenate and Febuxostat
Trial: 20963840
Drug: Azithromycin 10
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 10 mg/kg/day for 7 days followed by 5 mg/kg/day for a maximum of 6 weeks
Trial: 18320254
Drug: Genetically modified
RxNorm normalized name: Genetically modified virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically modified potatoes (3 mg zeaxanthin)
Trial: 18320254
Drug: Wild-type control
RxNorm normalized name: Influenza A virus A/Brisbane/10/2010 (H1N1) wild type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wild-type control potatoes (0.14 mg zeaxanthin)
Trial: 16233990
Drug: Lacto-ovo-vegetarian diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacto-ovo-vegetarian diet (32 treatment sessions over 12 months)
Trial: 9198292
Drug: nizatidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nizatidine (2 x 150 mg twice daily), amoxicillin (2 x 250 mg four times daily), clarithromycin (2 x 250 mg three times daily) for two weeks (niz-amox-clar group, N = 25)
Trial: 9198292
Drug: omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole (20 mg twice daily), clarithromycin (2 x 250 mg three times daily) for two weeks (ome-clar group, N = 25)
Trial: 9198292
Drug: bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bismuth subsalicylate (300 mg four times daily), amoxicillin (2 x 250 mg four times daily), metronidazole (250 mg four times daily) for two weeks (triple therapy group, N = 25)
Trial: 4085468
Drug: Digby‐Leigh valve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digby‐Leigh valve with inspiratory resistance of 7 cmH2O l‐1s and high expiratory resistance of 25 cmH2O l‐1s (DLS)
Trial: 4085468
Drug: Inspiratory resistive
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory resistive load of 12 cmH2O l‐1s (IRS1)
Trial: 4085468
Drug: Inspiratory resistive
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory resistive load of 25 cmH2O l‐1s (IRS2)
Trial: 29997249
Drug: Low-dose mTOR
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose mTOR inhibitor therapy (combination of BEZ235 and RAD001)
Trial: 22383266
Drug: Bergamot essential
RxNorm normalized name: Nature's Truth Bergamot Essential Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bergamot essential oil inhalation
Trial: 15877554
Drug: NITE-AD intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NITE-AD intervention (sleep hygiene education, daily walking, increased light exposure)
Trial: 12700935
Drug: Manipulation under
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manipulation under anaesthesia (MUA) with intra-articular normal saline injection
Trial: 12700935
Drug: Manipulation under
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manipulation under anaesthesia (MUA) with intra-articular methylprednisolone injection
Trial: 10472779
Drug: MPA (medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA (medroxyprogesterone acetate) at a daily total dose of 500 mg
Trial: 8758107
Drug: Rifampicin 600
RxNorm normalized name: Rifampicin 600 mg powder for solution for infusion vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 600 mg, Isoniazid 400 mg, and Pyrazinamide 1.25 g daily for 3 months
Trial: 1765317
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nalbuphine
Trial: 1451900
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg pethidine
Trial: 6751144
Drug: Intramuscular regime
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular regime
Trial: 30450637
Drug: 3K3A-APC at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3K3A-APC at 540 μg/kg
Trial: 26477023
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy and relaxation treatment (SHE treatment)
Trial: 23639598
Drug: RM-131 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RM-131 (100 μg, subcutaneously)